TAGRISSO (osimertinib)

TAGRISSO (osimertinib) is an EGFR TKI indicated for adult patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).1

References

  1. TAGRISSO Summary of Product Characteristics, May 2017.
  2. Mok TS et al. N Engl J Med. 2017; 376: 629−640.
  3. Diaz LA Jr and Bardelli A. J Clin Oncol. 2014; 32(6): 579−586.
  4. ESMO Clinical Practice Guidelines. Annals of Oncology 2016; 27(5): v1−v27.
  5. Ilie M and Hofman P. Transl Lung Cancer Res. 2016; 5(4): 420–423
  6. Wu YL et al. Jour Thoracic Oncol. 2017; 12(1): S386.
  7. Jenkins S et al. Abstract 134O. Presented at the 6th IASLC/ESMO European Lung Cancer Conference, 13–16 April 2016; Geneva: Switzerland.
  8. Yu HA et al. Clin Cancer Res. 2013; 19: 2240–2247.
  9. Langer CJ. J Clin Oncol. 2013; 31: 3303−3306.
  10. Oxnard GR et al. Clin Cancer Res. 2011; 17(6): 1616−1622.
  11. Arcila ME et al. Clin Cancer Res. 2011; 17(5): 1169−1180.
  12. Sun JM et al. Lung Cancer 2013; 82: 294−298.
  13. Kuiper JL et al. Lung Cancer 2014; 85: 19−24.
  14. Li W et al. Lung Cancer 2014; 84: 295−300.

GB-5898 - August 2017